Acromegaly Market Research Report Information: By Types (Ectopic Acromegaly, Acromegaly Due to Growth Hormone), By Diagnosis (Medical Imaging, Medical Laboratory Investigations), By Treatment (Medications, Surgery, Radiation Therapy), By End Users (Hospitals, Clinics) - Global Forecast till 2032

Global Acromegaly Market Overview

Acromegaly Market Size was valued at USD 1.54 Billion in 2023. The Global Acromegaly industry is projected to grow from USD 1.62 Billion in 2024 to USD 2.33 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.08% during the forecast period (2024 - 2032).

Acromegaly is a hormonal problem that outcomes from weighty emission of development chemicals (GH) in the body. The pituitary organ in the cerebrum secretes GH. In acromegaly, the pituitary produces unnecessary measures of GH. Normally, the overabundance of GH comes from harmless or noncancerous growths on the pituitary. These harmless cancers are called adenomas. Acromegaly is one of the intriguing illnesses, which is most frequently analyzed in moderately aged grown-ups and influences 5-8 individuals for every 1 lakh individuals.

Crinetics Pharmaceuticals CRNX shares gained 19.1% on March 19th, 2024, after the company announced positive top-line results from the second phase III clinical trial (PATHFNDR-2) investigating the safety and efficacy of their lead candidate palustrine in acromegaly treatment. Acromegaly is a rare hormonal disorder that typically occurs due to adenoma, which is a benign tumor that produces GH and affects the pituitary gland. PATHFNDR-2 investigates acromegalic patients who have not undergone any previous treatment or are not currently taking oral SST2 agonist paltusotine as part of their medical regimen. According to data disclosed, phase III PATHFNDR-2 investigation successfully achieved its primary endpoint with statistical significance demonstrating that the percentage of patients treated with paltusotine achieving normal insulin-like growth factor 1 (IGF-1) levels less than or equal to the one-fold upper limit for normality xULN was 56% versus placebo at 5%. Crinetics also revealed that all secondary endpoints were statistically significant.

Now, from September 2020, Mycapssa (octreotide delayed-release capsules; Chiasma) is available as a long-term maintenance therapy in acromegalic adults who have previously responded to octreotide or lanreotide treatments. For the past year, the FDA has approved an oral somatostatin analog called Mycapssa on the basis of stage 3 clinical trials [NCT03252353] among fifty-six adult patients with acromegaly whose disease was being managed by some injectable somatostatin analogs (octreotide or lanreotide) through IGF-1 levels. They found out that more people on Mycapssa still maintained their biochemical response at month nine than those on placebo (58% vs. 19%).

Ipsen declared today its plans to invest in a new state-of-the-art electronic autoinjector for Somatuline Autogel / Somatuline Depot (lanreotide) and drive further innovation in this class, aiming at better administration and injecting experience for patients. It will be designed together with the global leader in drug delivery design, development, and manufacturing solutions, Phillips-Medisize, and it will be accompanied by increased investments into Ipsen’s Signe's production site in France. This continues Ipsen’s experience of over two decades at Somatuline Autogel / Somatuline Depot, and it has become the fourth generation of devices that will enable them to deliver it. Nonetheless, despite technological advancements, real-life evidence shows that many still face pain and discomfort during injections used by patients with gastroenteropancreatic neuroendocrine tumors or acromegaly.

If the sicknesses are not treated, it can bring about difficult diseases and sudden passing. The most genuine well-being outcomes of the sickness might result in hypertension, type 2 diabetes, the expanded hazard of cardiovascular infection, joint inflammation, and others. The significant driving elements for the market are expanding commonness of acromegaly, evolving way of life, and expanding hereditary occurrence of hereditary infections. Also, expanding commonness of hormonal infections, for example, endocrine sicknesses and hypopituitarism, expanding government backing and fast improvements in innovation have fuelled the development of the market.

The rising prevalence of acromegaly, changing lifestyles, and rising rates of inherited illnesses are major factors propelling the market forward. The growth of the industry has been fueled by a number of factors, including the increasing prevalence of hormonal infections such as endocrine diseases and hypopituitarism, rising government support, and rapid advances in innovation. The rising global incidence and prevalence of acromegaly and pituitary tumors; rising global awareness of the condition; and technological advances in creating novel medications for acromegaly are also major drivers driving the market.

Over the past year and a half, most businesses throughout the world have seen negative effects. This is because their unique assembly and production network activities were severely disrupted due to various lockdowns and restrictions imposed by supervising specialists in different parts of the world.

The global Acromegaly Treatment market is similar. The general financial condition of most people has been badly hit by this outbreak, and as a result, consumer demand has reduced as people are presently quicker on eliminating superfluous costs from their own budgets.

With this breakthrough, they may be able to get into the lucrative market for Cushing's syndrome and acromegaly treatments. Product adoption for Cushing's syndrome and acromegaly is anticipated to be pushed forward by the development of targeted pharmacological treatment with minimal side effects. Different variables are likely to promote the growth of the market for Cushing's Syndrome and Acromegaly treatment, such as the assistance to vagrant infections and imaging by the states of various nations.

June 2023: Global leader in the research and development of therapeutic peptides for rare endocrine and related diseases, Amolyt Pharma, has announced the start of a Phase 1 clinical trial for its peptide growth hormone receptor antagonist (GHRA), AZP-3813, in the treatment of acromegaly. Since somatostatin analogs have been shown to reduce IGF-1 levels and regulate remaining tumor growth, they are considered first-line therapy in the pharmacological management of acromegaly.

Covid-19 Analysis:

Most enterprises across the world have been contrarily affected in the course of the most recent year and a half. This can be ascribed to critical interruptions experienced by their particular assembling and production network activities because of different preparatory lockdowns, as well as different limitations that were implemented by overseeing specialists across the globe.

A similar applies to the worldwide Acromegaly Treatment market. Additionally, shopper request has likewise, along these lines, decreased as people are presently quicker on disposing of unnecessary costs from their particular spending plans as the overall monetary status of most people have been seriously impacted by this flare-up.

These previously mentioned components are relied upon to trouble the income direction of the worldwide Acromegaly Treatment market over the conjecture timetable. Be that as it may, as individual administering specialists lift these implemented lockdowns, the worldwide Acromegaly Treatment market is relied upon to recuperate as needs are.

Chief Factors Existing in The Acromegaly Market:

• Key Market Drivers:

Segment drivers incorporate the maturing of the total populace and the developing medical care use all over the planet. The backslide rates for Cushing's Syndrome and Acromegaly after the medical procedure is pretty much as high as 15 to 20 %, which is one more driver of the Cushing's Syndrome and Acromegaly therapy market.

New medications in the market enlarge the selection of treatments for specialists and patients. In 2017, Midatech Pharma PLC submitted a preliminary clinical application in the human investigation of the Q-Octreotide (MTD201) program in malignant growth and acromegaly, and presently it has gotten oral affirmation from Polish controllers for its endorsement in January 2018.

Besides, Chiasma Inc's new oral upkeep treatment for acromegaly treatment named Mycapssa has finished a global Phase 3 preliminary and further directing a worldwide Phase 3 clinical preliminary under a convention acknowledged by the European Medicines Agency (EMA) for grown-up patients with acromegaly is likewise expected to help the development of acromegaly treatment market over the estimate time frame. A lapse of medication licenses during the conjecture time frame can hamper the market briefly.

• Acromegaly Market Challenges:

The rising mindfulness about acromegaly and an expansion in the paces of screening are among the superb driver of the acromegaly treatment market. In addition, headways in a medical procedures and the development of other options, like radiation treatment, meds and others, are driving the acromegaly therapy market. Free improvements in clinical conclusion, for example, attractive reverberation imaging and the IGF1 and GH concealment test, give the most touchy and particular means for the testing of acromegaly.

Headways in meds, which incorporate the improvement of adversaries, for example, somatostatin analogs, dopamine agonists and GH receptor bad guys, which are the manufactured types of normal chemicals that limit the development of GH, is driving the Acromegaly Treatment market towards painless medicines, particularly in situations where the medical procedure isn't plausible.

• Market Opportunities:

Innovation gains in the huge market a potential open door for their Cushing's Syndrome and Acromegaly market outlook. The advancement of designated drug treatment with insignificant incidental effects is relied upon to drive the reception of Cushing's Syndrome and Acromegaly treatment items. The help to vagrant infections and imaging by the states of various nations is different variables expected to support the development of the market for Cushing's Syndrome and Acromegaly treatment.

• Acromegaly Market Restraints:

The high achievement pace of treatment is driving the reception of acromegaly treatment, and future after the effective treatment of acromegaly is equivalent to typical.

In any case, the significant expense of a medical procedure, which goes from USD 3000 to USD 9,000, and trouble in visualization that must be done on a singular premise are among the factors expected to control the development of the Acromegaly Treatment market. Besides, entanglements related to the treatment, like the gamble of disease, torment and disabled insusceptibility, are probably going to control the development of the acromegaly treatment market.

Acromegaly Market Segmentation:

Acromegaly market share is fragmented based on types, analysis, treatment, and end clients.

Based on types, the market is fragmented into ectopic acromegaly, acromegaly because of the development of chemicals, and others.

Based on the diagnosis, the Acromegalymarket analysis is fragmented into clinical imaging, clinical lab examinations, and others. Clinical imaging is additionally divided into radiography, attractive reverberation imaging (MRI), atomic medication, ultrasound, and others.

Based on treatment, the market is portioned into drugs, medical procedures, radiation treatment, and others. The medicine is additionally portioned into somatostatin analogs, dopamine agonists, development chemical receptor enemies, and others. The medical procedure is additionally sectioned into the endonasal transsphenoidal medical procedure and transsphenoidal medical procedure.

Based on end user, the market is sectioned into medical clinics, facilities, and others.

January 2023: The US Food and Drug Administration (FDA) released proposed advice to help drug companies create treatments for acromegaly in patients who have not responded to surgery or who are in poor health. Current FDA-approved treatments for acromegaly include a GH-receptor antagonist (pegvisomant), a dopamine-receptor agonist (bromocriptine), and somatostatin analogs (octreotide, lanreotide, and pasireotide). Eligibility criteria, efficacy assessment, safety considerations, and statistical considerations are just some of the topics addressed in the draft guidance for designing Phase 3 studies of treatments for acromegaly.

Acromegaly Market Regional Analysis:

Topographically, the acromegaly market growth is fragmented into five significant areas, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa district.

North America, overwhelmed by the U.S., represents the biggest market in the worldwide acromegaly treatment market in the gauge time frame. This is credited to variables, for example, the accessibility of repayment, ideal government arrangements, an expansion in the event of pituitary growths in the district prompting acromegaly and gigantism, innovative progressions, and rising mindfulness among individuals around the conclusion of the infection in the locale.

Europe is the second biggest income supporter in the worldwide acromegaly treatment market, which is assessed to be driven by Germany, France, and the U.K. The European areas have a huge medical care foundation with numerous predominant market players working on the lookout.

Asia-Pacific is assessed to develop at a quick rate during the conjecture time frame. Factors like a developing economy, rising discretionary cash flow, expanding populace, rising mindfulness, R&D drives, and expanding ventures by the drug organizations are projected to introduce worthwhile learning experiences during the figure time frame.

In the Middle East and Africa, the acromegaly treatment market is relied upon to be overwhelmed by the prosperous Gulf economies of Saudi Arabia, Kuwait, UAE, and Qatar. Notwithstanding, the oppressed pay of African economies, along with unfortunate group environments, could hinder the acromegaly treatment market in Africa.

Acromegaly Market Competitive Landscape:

Some of key the players included in the acromegaly market value are Novartis AG (Switzerland), Aegis Therapeutics LLC (US), Chiasma Inc (US), Crinetics Pharmaceuticals Inc (US), Daewoong Pharmaceutical Co Ltd (South Korea), Peptron Inc (South Korea), Silence Therapeutics Plc (UK), Strongbridge Biopharma plc (US), Amryt Pharma plc (UK), Foresee Pharmaceuticals LLC (US), Glide Pharmaceutical Technologies Ltd (US), Ionis Pharmaceuticals Inc (US), Ipsen SA (France)

Recent Market Developments:

• Mar 2020: Chiasma, a clinical-stage biopharmaceutical organization, is fostering an oral type of the medication octreotide for the upkeep treatment of acromegaly in grown-ups which is not yet supported by the U.S. FDA. As per their exploration, octreotide containers can possibly function as an option in contrast to flow infusion treatment.


• Mar 2019: Ipsen communicated their EU send-off of another pre-filled needle for the drug Somaline, which is utilized for the treatment of acromegaly.

Acromegaly Market Report Overview:

Acromegaly market forecast report gives an exhaustive comprehension of Acromegaly by including subtleties like sickness definition, side effects, causes, pathophysiology, determination, and therapy. Acromegaly is an intriguing, gradually moderate, obtained problem that influences grown-ups.

The pituitary organ delivers an excessive amount of development chemicals (GH). The pituitary organ is a little organ situated close to the foundation of the skull that stores a few chemicals and deliveries them into the circulatory system on a case-by-case basis by the body. These chemicals direct a wide range of physical processes.

In many patients, acromegaly market trends are brought about by the development of a harmless growth (adenoma) emerging from the pituitary organ. Side effects of acromegaly remember the strange expansion of bones of the hands, arms, feet, legs, and head. Growth of the bones in the jaws and the front of the skull are normally the most obvious hard changes.

Normal signs and side effects of acromegaly are developed hands and feet. For instance, patients can't put on rings that used to fit, and the shoe size has logically expanded. It might likewise cause continuous changes in the face shape, for example, a projecting lower jaw and temple bone, an expanded nose, thickened lips, and more extensive separation between the teeth.

Key Segments:

On the basis of product type, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:

• Somatostatin Analogues


• Dopamine Agonists


• Growth Hormone Receptor Antagonists


• Other

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including:

• Hospitals


• Clinics

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth rate of Acromegaly in these regions

• North America (the United States, Canada and Mexico)


• Europe (Germany, UK, France, Italy, Russia and Turkey etc.)


• Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)


• South America (Brazil, Argentina, Columbia etc.)


• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)